COVID-19 |  Discovery of "ultra-potent" antibody that blocks multiple variants of the coronavirus

Scientists from the University Hospital of Lausanne and the Federal Polytechnic School of that Swiss city (EPFL) announced today the discovery of a monoclonal antibody capable of neutralizing all variants of the SARS-CoV-2, including the Delta.

SIGHT: The WHO officially defines persistent COVID-19 as a disease: what symptoms does it present?

The scientific finding, published in the specialized journal “Cell Reports”, It has been achieved by isolating lymphocytes from COVID-19 patients.

The antibody is “One of the most powerful so far identified against the SARS-CoV-2 coronavirus”EPFL said in a statement.

SIGHT: CureVac Cancels Initial COVID-19 Vaccine Project

As he explained, the antibody blocks spike proteins (which give the virus its characteristic “corona” shape) and thereby prevent it from infecting lung cells, which stops the viral replication process and allows the patient’s immune system to eliminate the coronavirus from the body.

The scientists also assure that the new monoclonal antibody is more durable, since it provides protection for around six months, against three or four weeks for other antibodies.

SIGHT: Sputnik V: what you should know about its possible approval before the WHO

”This makes it an interesting preventive treatment for unvaccinated individuals at risk, or for vaccinated people who have not been able to produce an immune response ”, said the communiqué of the Swiss university.

Immunocompromised patients, recipients of a transplanted organ or patients of certain types of cancer They could be protected against the coronavirus by receiving injections of the discovered antibody two or three times a year, EPFL experts predicted.

Clinical trials of a drug based on these antibodies will begin in late 2022.

RELATED VIDEO

IT MAY INTEREST YOU:

  • The WHO officially defines persistent COVID-19 as a disease: what symptoms does it present?
  • CureVac Cancels Initial COVID-19 Vaccine Project
  • Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says
  • Merck Pill Treatment May Be New Weapon Against COVID-19, WHO Says
  • COVID-19 | Why do WHO experts say that the Sinopharm vaccine requires three doses?
  • Pfizer and AstraZeneca Vaccines Reduce Risk of Severe COVID-19 by 90%, Study Confirms
  • AstraZeneca Experimental Drug Reduces Severe COVID-19 Cases or Death by 67%
  • Molnupiravir | What You Should Know About MSD’s COVID-19 Pill
  • Ivermectin: How Fake Science Invented a “Miracle” Drug Against COVID-19
  • Third dose reduces the risk of severe illness from COVID-19 by 96%, according to Chilean study
  • What to answer to those who still doubt whether to get vaccinated against COVID-19
  • COVID-19 | Argentina starts vaccination with Sinopharm in children between 3 and 11 years old
  • Everything we know about COVID-19 so far
  • COVID-19 | What causes a patient in ICU to die?
  • One in eight people suffered from mental disorders in Lima due to the COVID-19 pandemic

Follow us on twitter:


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

Leave a Reply